CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.220
0.00 (0.05%)
Jan 23, 2025, 4:00 PM EST

CytoDyn Company Description

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications.

The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure.

The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

CytoDyn Inc.
CytoDyn logo
Country United States
Founded 2002
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Jacob Lalezari

Contact Details

Address:
1111 Main Street
Vancouver, Delaware 98660
United States
Phone 360 980 8524
Website cytodyn.com

Stock Details

Ticker Symbol CYDY
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year June - May
Reporting Currency USD
ISIN Number US23283M1018
SIC Code 2836

Key Executives

Name Position
Dr. Jacob P. Lalezari M.D. Chief Executive Officer and Member of Scientific Advisory Board
Mitchell Cohen Interim Chief Financial Officer
Tyler Blok Chief Legal Officer and Corporate Secretary
Dr. Cyrus Arman M.B.A., Ph.D. Senior Vice President of Business Operations
Dr. Bernie Cunningham P.M.P., Ph.D. Vice President of Operations
Dr. Scott Hansen Ph.D. Head of Research and Basic Science
Dr. Max Lataillade D.O., M.P.H. Senior Vice President and Head of Clinical Development
Cristina De Leon Investors